230 related articles for article (PubMed ID: 30374517)
21. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
[TBL] [Abstract][Full Text] [Related]
22. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography.
Buchler T; Simonova K; Fencl P; Jarkovsky J; Abrahamova J
Cancer Invest; 2012 Jul; 30(6):487-92. PubMed ID: 22506657
[TBL] [Abstract][Full Text] [Related]
24. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients.
Cremerius U; Wildberger JE; Borchers H; Zimny M; Jakse G; Günther RW; Buell U
Urology; 1999 Nov; 54(5):900-4. PubMed ID: 10565755
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer: a meta-analysis.
Zhao JY; Ma XL; Li YY; Zhang BL; Li MM; Ma XL; Liu L
Asian Pac J Cancer Prev; 2014; 15(8):3525-31. PubMed ID: 24870751
[TBL] [Abstract][Full Text] [Related]
26. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
[TBL] [Abstract][Full Text] [Related]
27. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
[TBL] [Abstract][Full Text] [Related]
28. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.
Treglia G; Sadeghi R; Annunziata S; Caldarella C; Bertagna F; Giovanella L
Biomed Res Int; 2014; 2014():852681. PubMed ID: 24963486
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET/CT impact on testicular tumours clinical management.
Ambrosini V; Zucchini G; Nicolini S; Berselli A; Nanni C; Allegri V; Martoni A; Rubello D; Cricca A; Fanti S
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):668-73. PubMed ID: 24265073
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment.
Raggi D; Bandini M; Giannatempo P; Farè E; Marandino L; Colecchia M; Calareso G; Padovano B; Serafini G; Alessi A; Necchi A
Clin Genitourin Cancer; 2021 Jun; 19(3):237-245.e2. PubMed ID: 32980271
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
33. PET imaging in testicular tumours.
Calabrò D; Telo S; Ambrosini V
Curr Opin Urol; 2020 Sep; 30(5):665-671. PubMed ID: 32732623
[TBL] [Abstract][Full Text] [Related]
34. [Positron emission tomography in the diagnosis and monitoring of patients with nonseminomatous germ cell tumours].
Büchler T; Simonová K; Fencl P; Abrahámová J
Klin Onkol; 2011; 24(6):413-7. PubMed ID: 22257229
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
[TBL] [Abstract][Full Text] [Related]
36. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Loriot Y; Texier M; Culine S; Fléchon A; Thiery-Vuillemin A; Gravis G; Geoffrois L; Chevreau C; Gross-Goupil M; Barthelemy P; Bompas E; Mahammedi H; Laguerre B; Lacourtoisie SA; Helissey C; Ladoire S; Abraham C; Massard C; Grimaldi S; Fizazi K
Eur Urol; 2022 Aug; 82(2):172-179. PubMed ID: 35599187
[TBL] [Abstract][Full Text] [Related]
37. [A Case of Metastatic Seminomatous Testicular Tumor with Complicated Diagnosis by FDG-PET].
Hashizume A; Mizuno N; Kawai M; Kishida T
Hinyokika Kiyo; 2016 Jul; 62(7):383-7. PubMed ID: 27569358
[TBL] [Abstract][Full Text] [Related]
38. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
Pfannenberg AC; Oechsle K; Bokemeyer C; Kollmannsberger C; Dohmen BM; Bares R; Hartmann JT; Vonthein R; Claussen CD
World J Urol; 2004 Jun; 22(2):132-9. PubMed ID: 14735310
[TBL] [Abstract][Full Text] [Related]
39. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
[TBL] [Abstract][Full Text] [Related]
40. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]